

Western Australian Aboriginal Immunisation Schedule

Childhood

Age/Eligibility	Antigen/Antibody	Brand(s)	Important information	
Birth to <7 days	Nirsevimab*	Beyfortus [®]	Aboriginal babies born 1/5/24 to 31/3/25 and residing in, or about to imminently reside in, the Kimberley or Pilbara region	
	Hepatitis B	H-B-Vax [®] II Paed or Engerix [®] B Paed		
6-8 weeks	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®		
	13vPCV	Prevenar® 13		
	Rotavirus	Rotarix®	Oral dose 1: Must be given by 14 weeks of age	
	MenACWY*	Nimenrix®		
	MenB	Bexsero®	Prophylactic paracetamol recommended	
4 months	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®]	
	13vPCV	Prevenar® 13		
	Rotavirus	Rotarix®	Oral dose 2: Must be given by 24 weeks of age	
	MenACWY*	Nimenrix®		
	MenB	Bexsero®	Prophylactic paracetamol recommended	
6 months	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®		
	13vPCV	Prevenar® 13		
1450	MenB	Bexsero®	Prophylactic paracetamol recommended	
MRC	MenACWY	Nimenrix®		
12 months	MMR	MMRII® or Priorix®	2	
	13vPCV	Prevenar® 13		
	MenACWY	Nimenrix®	-	
	MenB	Bexsero®	Prophylactic paracetamol recommended	
MRC	Hepatitis B	H-B-Vax [®] II Paed or Engerix [®] B Paed	<32 weeks gestation or <2000g birth weight	
All children >12 months with MRC	Children diagnosed with MRC at >12 months of age require 1 dose of 13vPCV at diagnosis, followed by a first dose of 23vPPV, 2 to 12 months later or at 4 years of age, whichever is later. A second dose of 23vPPV is given 5 years later. See Australian Immunisation Handbook			
18 months	DTPa	Infanrix® or Tripacel®		
300	Hib	ActHIB®		
	MMRV	Priorix-Tetra®	Do not adminster MMRV as dose 1 of a measles-containing vaccine if <4 years of age	
	Hepatitis A	Vaqta® Paed/Adol		
<2 years	Catch-up for MenB is a	vailable for Aboriginal children	<2 years of age	
4 years	DTPa-IPV	Quadracel® or Infanrix®IPV		
	Hepatitis A	Vaqta® Paed/Adol	Not required if previously received 2 doses (first dose at age ≥12 months) at least 6 months apart	
See footnotes at bottom of page 3	23vPPV	Pneumovax23®	First dose (if not previously received) followed by second dose at least 5 years later	

health.wa.gov.au

Respiratory Syncytial Virus (RSV)

Age/Eligibility	Antigen/Antibody	Brand	Important information
All Aboriginal children aged less than 19 months who have not previously received nirsevimab	Nirsevimab*	Beyfortus®	Dosage: For any Aboriginal infant less than 8 months of age who has not previously received nirsevimab, dosage is determined by weight (50mg for infants <5kg and 100mg for infants ≥5kg). For all Aboriginal children and those with MRC aged 8 months to less than 19 months who have not previously received nirsevimab, dosage is 200mg (2x100mg doses). For list of MRC please see Respiratory Syncytial Virus (RSV) immunisation.

Adolescent and adult

Age/Eligibility	Antigen	Vaccine brand(s)	Important information	
All adolescents and adults with MRC	Adolescents and adults diagnosed with MRC require a first dose of 23vPPV, 2 to 12 months later. A second People of all ages with specified MRC are eligible for		l dose is given at least 5 years later.	
Year 7	HPV	Gardasil®9	Catch-up for adolescents < 26 years of age	
	dTpa	Boostrix® or Adacel®		
Year 10	MenACWY	Nimenrix® or MenQuadfi		
≥18 years MRC	Herpes-zoster	Shingrix [®]	2 doses, given 1–2 months apart	
Pregnant	dTpa	Boostrix® or Adacel®	Each pregnancy, ideally between 20–32 weeks	
	RSV	Abrysvo [®]	Eligible women between 28 - 36 weeks	
≥20 years	Hepatitis B	Engerix® B	For non-immune persons. See the <u>Australian</u> <u>Immunisation Handbook</u> for recommendations and timing of doses	
≥50 years	13vPCV	Prevenar [®] 13	See the Australian Immunisation Handbook	
	23vPPV	Pneumovax23®	for timing of doses	
	Herpes-zoster	Shingrix [®]	2 doses, given 2-6 months apart	
Born after 1965*	MMR	Priorix®	Give 1 or 2 doses as required. Whilst serology is not routinely recommended, see WA adult measles vaccination program for details.	

health.wa.gov.au 2

Seasonal influenza

Age/Eligibility	Vaccine brand(s)	Important information	
6 months to <5 years	Vaxigrip®Tetra, Fluarix®Tetra	For children <9 years or persons with MRC, 2 doses required 1 month apart in the first year they receive influenza vaccine.	
5 years to <65 years	Vaxigrip®Tetra, Fluarix®Tetra, Flucelvax®Quad	One dose annually in subsequent years. For information on specified MRC see the <u>Australian</u> <u>Immunisation Handbook</u> or annual <u>ATAGI advice</u> on seasonal influenza vaccines.	
Pregnancy	Vaxigrip®Tetra, Fluarix®Tetra, Flucelvax®Quad	Each pregnancy, any trimester	
≥65 years	Fluad® Quad	Preferentially use adjuvanted QIV	
WA Health staff^*	Fluarix®Tetra, FluQuadri®	For ≥65 years use Fluad® Quad	



Using the term Aboriginal

Within Western Australia, the term Aboriginal is used in preference to Aboriginal and Torres Strait Islander, in recognition that Aboriginal people are the original inhabitants of Western Australia. Aboriginal and Torres Strait Islander may be referred to in the national context and Indigenous may be referred to in the international context. No disrespect is intended to our Torres Strait Islander colleagues and community.


References

- * Refers to WA State-funded Programs.
- ^ Refers to all persons attending WA Health staff influenza vaccination services.

MRC refers to people with medical risk conditions. Refer to the current online edition of The <u>Australian Immunisation Handbook</u> for all medical risk conditions, recommendations and timing of doses.

Persons aged <20 years can catch-up scheduled vaccines, refer to Australian Immunisation Handbook for timing of doses.

This document can be made available in alternative formats on request.



Produced by the Communicable Disease Control Directorate © Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the *Copyright Act 1968*, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.

IMM-013757v1 JAN'25